Journal of Clinical Oncology, Vol 22, No 12 (June 15), 2004: pp. 2363-2370
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.10.077
Tumor-Specific Methylation in Bronchial Lavage for the Early Detection of Non-Small-Cell Lung Cancer
Hojoong Kim,
Young Mi Kwon,
Jin Seuk Kim,
Haengbyoung Lee,
Jung-Ho Park,
Young Mog Shim,
Joungho Han,
Joobae Park,
Duk-Hwan Kim
From the Division of Pulmonary and Critical Care Medicine, Department of Thoracic Surgery, and Department of Pathology, Samsung Medical Center, Sungkyunkwan University, School of Medicine; Center for Genome Research, Samsung Biomedical Research Institute, Seoul; and Department of Molecular Cell Biology, Sungkyunkwan University, School of Medicine, Suwon, Korea
Address reprint requests to Duk-Hwan Kim, MD, Center for Genome Research, Samsung Biomedical Research Institute, Rm B155, #50 Ilwon-dong, Kangnam-Ku, Seoul, Korea, 135-710; e-mail: dukhwan{at}samsung.co.kr
PURPOSE: The aim of this study was to identify tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer (NSCLC) by differentiating the age-related methylation from the tumor-specific methylation in NSCLC.
PATIENTS AND METHODS: Eighty-five NSCLC patients and 127 cancer-free subjects participated in this study. Aberrant methylation at the promoters of the p16, Ras association domain family 1A (RASSF1A), fragile histidine triad (FHIT), H-cadherin, and retinoic acid receptor ß (RARß) genes were evaluated in the resected tumor tissues and bronchial lavage samples of NSCLC patients and in the bronchial lavage samples of cancer-free subjects by methylation-specific polymerase chain reaction.
RESULTS: Of the 127 cancer-free samples, methylation was detected in 6% for p16, 13% for RARß, 3% for H-cadherin, 4% for RASSF1A, and 28% for FHIT. Hypermethylation of the p16, RARß, H-cadherin, and RASSF1A genes was not associated with patient age and smoking, whereas hypermethylation of the FHIT promoter occurred more frequently in older patients (P = .02) and was associated with exposure to tobacco smoke (P = .001). A strong correlation between age and smoking was found in patients with hypermethylation of the FHIT gene (r = 0.36; P = .03). A total of 68% of the bronchial lavage samples from the 85 NSCLC patients showed methylation of at least one of p16, RARß, H-cadherin, and RASSF1A genes.
CONCLUSION: Our study suggests that tumor-specific methylation of the p16, RASSF1A, H-cadherin, and RARß genes may be a valuable biomarker for the early detection of NSCLC in bronchial lavage, and that the age-related methylation of FHIT gene in the normal bronchial epithelium is related to the exposure to tobacco smoke.
Supported by the Samsung Biomedical Research Institute, Seoul; and Samsung Advanced Institute of Technology, Suwon, Korea.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
This article has been cited by other articles:

|
 |

|
 |
 
S. Umemura, N. Fujimoto, A. Hiraki, K. Gemba, N. Takigawa, K. Fujiwara, M. Fujii, H. Umemura, M. Satoh, M. Tabata, et al.
Aberrant promoter hypermethylation in serum DNA from patients with silicosis
Carcinogenesis,
September 1, 2008;
29(9):
1845 - 1849.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Barlesi, G. Giaccone, M. I. Gallegos-Ruiz, A. Loundou, S. W. Span, P. Lefesvre, F. A.E. Kruyt, and J. A. Rodriguez
Global Histone Modifications Predict Prognosis of Resected Non Small-Cell Lung Cancer
J. Clin. Oncol.,
October 1, 2007;
25(28):
4358 - 4364.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Righini, F. de Fraipont, J.-F. Timsit, C. Faure, E. Brambilla, E. Reyt, and M.-C. Favrot
Tumor-Specific Methylation in Saliva: A Promising Biomarker for Early Detection of Head and Neck Cancer Recurrence
Clin. Cancer Res.,
February 15, 2007;
13(4):
1179 - 1185.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. De Flora, F. D'Agostini, A. Izzotti, N. Zanesi, C. M. Croce, and R. Balansky
Molecular and Cytogenetical Alterations Induced by Environmental Cigarette Smoke in Mice Heterozygous for Fhit
Cancer Res.,
February 1, 2007;
67(3):
1001 - 1006.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Worsham, K. M. Chen, V. Meduri, A. O. H. Nygren, A. Errami, J. P. Schouten, and M. S. Benninger
Epigenetic events of disease progression in head and neck squamous cell carcinoma.
Arch Otolaryngol Head Neck Surg,
June 1, 2006;
132(6):
668 - 677.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Kim, J. W. Kim, J. Han, Y. M. Shim, J. Park, and D.-H. Kim
Cohypermethylation of p16 and FHIT Promoters as a Prognostic Factor of Recurrence in Surgically Resected Stage I Non-Small Cell Lung Cancer.
Cancer Res.,
April 15, 2006;
66(8):
4049 - 4054.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. D'Agostini, A. Izzotti, R. Balansky, N. Zanesi, C. M. Croce, and S. De Flora
Early loss of fhit in the respiratory tract of rodents exposed to environmental cigarette smoke.
Cancer Res.,
April 1, 2006;
66(7):
3936 - 3941.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. O. Hoque, E. Rosenbaum, W. H. Westra, M. Xing, P. Ladenson, M. A. Zeiger, D. Sidransky, and C. B. Umbricht
Quantitative Assessment of Promoter Methylation Profiles in Thyroid Neoplasms
J. Clin. Endocrinol. Metab.,
July 1, 2005;
90(7):
4011 - 4018.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Izumi, J. Inoue, S. Yokoi, H. Hosoda, T. Shibata, M. Sunamori, S. Hirohashi, J. Inazawa, and I. Imoto
Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers
Hum. Mol. Genet.,
April 15, 2005;
14(8):
997 - 1007.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|